期刊文献+

双氢青蒿素诱导鼻咽癌CNE-2细胞凋亡及其机制 被引量:4

Apoptosis of nasopharyngeal carcinoma cells line CNE-2 induced by dihydroartemisinin and its possible mechanism
原文传递
导出
摘要 目的:探讨双氢青蒿素(DHA)对鼻咽癌CNE-2细胞的生长抑制作用及其机制。方法:以体外培养的CNE-2细胞为研究对象,分别采用CCK-8法观察不同浓度和时间DHA对CNE-2细胞增殖的抑制作用,流式细胞仪Annexin V-FITC法检测CNE-2细胞的凋亡率,caspase-3活性检测法检测不同浓度DHA处理后CNE-2细胞中caspase-3的活性变化。结果:CCK-8法显示,与对照组相比,随DHA浓度的增加,CNE-2细胞的增殖显著抑制(P<0.05);流式细胞仪Annexin V-FITC法,结果显示DHA诱导CNE-2细胞凋亡具有浓度依赖性;caspase-3活性检测法显示,与对照组相比,随DHA浓度的增加,caspase-3的活性显著提高(P<0.05)。结论:DHA能有效抑制CNE-2细胞的增殖并诱导其凋亡,其机制可能是能上调CNE-2细胞中caspase-3的活性。 Objective: Dihydroartemisinin is a traditional anti-malarial drug, a derivative of the artemisinin,it has anti tumor activity of a variety of tumor cells. This study investigated the effect of growth inhibition of naso- pharyngeal carcinoma cells line CNE 2 induced by dihydroartemisinin and its possible mechanism. Method: The effect of DHA on the cell proliferation of CNE-2 was detected by CCK-8 assay with different concentrations and time. The effects of DHA on the cell apoptosis of CNE 2 were detected by Annexin V FITC assay through flow cy tometry and caspase 3 activity assay. Result: CCK-8 experimental results show that CNE-2 cell proliferation was suppressed with DHA treatment, as compared with the control group. DHA could induce marked apoptosis in CNE 2 by apoptosis assay, as compared with the control group, The percentages of apoptotic cells increased along with the increase of DHA concentrations in CNE 2;The activity of caspase 3 was increased following DHA treat ment in a dose-dependent manner;Conclusion: DHA could effectively inhibit proliferation and induce apoptosis of human nasopharyngeal carcinoma cells line CNE 2,the possible mechanism DHA induce apoptosis of CNE 2 cells by upregulating the expression of caspase 3.
出处 《临床耳鼻咽喉头颈外科杂志》 CAS 北大核心 2013年第13期717-720,共4页 Journal of Clinical Otorhinolaryngology Head And Neck Surgery
基金 广东省科技计划项目(No:93036)
关键词 鼻咽癌 双氢青蒿素 凋亡 CASPASE-3 nasopharyngeal carcinoma dihydroartemisinin apoptosis caspase-3
  • 相关文献

参考文献13

  • 1CAPONIGRO F, LONGO F, IONNA F, et al.Treatment approaches to nasopharyngeal carcinoma :a review[J]. Anticancer Drugs,2010,21 :471 —477.
  • 2EFFERTH T, DUNSTAN H, SAUERBREY A, etal. The anti-malarial artesunate is also active againstcancer[J]. Int J Oncol,2001,18 : 767 — 773.
  • 3EFFERTH T. Molecular pharmacology andpharma-cogenomics of artemisinin and its derivatives in canc-er cells [J]. Curr Drug Targets, 2006 ,7 :407 — 421.
  • 4曹培国,王肇炎.青蒿素及其衍生物的抗肿瘤作用[J].肿瘤防治杂志,2004,11(6):666-668. 被引量:15
  • 5CHEN H,SUN B, PAN S, et al. Dihydroartemisinininhibits growth of pancreatic cancer cells in vitro andin vivo[J]. Anticancer Drugs, 2009,20: 131 — 140.
  • 6JIAO Y,GE C M, MENG Q H,et al. Dihydmarte-misinin is an inhibitor of ovarian cancer cell growth[J]. Acta Pharmaeol Sin,2007 ,28 : 1045 — 1056.
  • 7CHEN H,SUN B, WANG S,et al. Growth inhibi-tory effect's of dihydroartemisinin on pancreatic canc-er cells : involvement of cell cycle arrest and inactiva-tion of nuclear factor-kappaB[J]. J Cancer Res ClinOncol, 2010,136: 897 — 903.
  • 8MAO H, GU H, QU X, et al. Involvement of themitochondrial pathway and Bim/Bcl-2 balance in di-hydroartemisinin-induced apoptosis in human breastcancer in vitro[J]. Int J Mol Med,2013,31: 213 —218.
  • 9LU J, CHEN S M, ZHANG X W, et al. The anti cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells[J]. In vest New Drugs, 2011, 29.. 1276--1283.
  • 10ZHANG C Z, ZHANG H, YUN J, et al. Dihydroar temisinin exhibits antitumor activity toward hepatocel- lular carcinoma in vitro and in vivo[J]. Biochem Pharmacol. 2012, 83:1278 1289.

二级参考文献15

  • 1杨小平,潘启超,梁永钜,张以琳.青蒿酯钠的抗肿瘤作用[J].癌症,1997,16(3):186-187. 被引量:57
  • 2Lai H, Singh N P. Selective cancer cellcytotoxicity from exposure to dihydroartemisinin andholotransferrin [J]. Cancer Lett,1995,91(4) :41-46.
  • 3Singh N P,Lai H. dihydroartemisinin and holotransferrin[J]. Li feSciences, 2001,70: 49 - 56.
  • 4Efferth T,Dunstan H,Sauerbrey A,et al. Theanti-malarial arte sunate is also active againstcancer[J]. Int J Oncol,2001,18(4):767-773.
  • 5Moore J C,Lai H,Li J R,et al. Oraladministration of dihydroartemisinin and ferroussulfate retarded implanted fibrosarcoma growth in therat[J]. Cancer Lett, 1995,98(1): 83 - 87.
  • 6Woerdenbag H J,Moskal T A,Pras N,et al. Cytotocicity of artemisinin-related endoperoxides toEhrlich ascites tumor cells[J]. J Nat Prod,1993,56(6) :849-856.
  • 7Beekman A C,Woerdenbag H J, Uden W V,et al. Stability of artemisinin in aqueousenvironments:impact on its cytotoxic action to Ehrlich ascites tumour cells[J]. J Pharm Pharmacol, 1997, 49 (12):1254-1258.
  • 8Lee C H,Hong H,Shin J,et al. NMR studiesonnovel antitumor drug candidates, Deoxoartemisinin andcarboxypropyl deoxoartemisinin[J]. Biochem BiophysRes Commun, 2000,274 (2): 359 -369.
  • 9Li Y,Shan F,Wu J M,et al. Novel antitumorar temisinin derivatives targeting G1 phase of the cell cycle[J]. Bioorg Med Chem Lett,2001,11(1) :5-8.
  • 10Wu J,Shan F,Wu G,et al. Synthesis and cytotoxicity of artemisinin derivatives containing cyanoarylmethyl group[J]. Eur J Med Chem,2001,36(5) :467-479.

共引文献14

同被引文献41

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部